Thus, careful baseline assessment of cardiovascular risk factors and genetic risk factors including the IDH mutation status as well as baseline measurement of cardiac function by a cardio-oncology specialist team should be performed in these AML patients (especially when adjuvant anthracyclines are used). This evidence concerns the gene IDH1 and acute myeloid leukemia.